France (FR)

Gaining Insights on the H2-Sorbent Interactions: Robust soc-MOF Platform as a Case Study. (2016) Cairns AJ, Eckert J, Wojtas L, Thommes M, Wallacher D, Georgiev PA, Forster PM, et al. Journal article, Original article Sensitivity of CO oxidation toward metal oxidation state in ceria-supported catalysts: an operando DRIFTS-MS study (2016) Kaftan A, Kollhoff F, Thanh-Son Nguyen , Piccolo L, Laurina M, Libuda J Journal article Transduction of Herpesvirus saimiri-Transformed T Cells with Exogenous Genes of Interest (2016) Martínez-Barricarte R, De Jong SJ, Markle J, De Paus R, Boisson-Dupuis S, Bustamante J, Van de Vosse E, et al. Journal article Conodonts from the Lower Ordovician of Morocco – a contribution to the faunal diversity in the famous Fezouata Lagerstätte (2016) Lehnert O, Nowak H, Sarmiento G, Servais T, Gutiérrez-Marco JC, Akodad M Journal article Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials (2016) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Conference contribution OBSERVATIONAL STUDY OF OUTCOME IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS TREATED WITH IMMUNOSUPPRESSIVE THERAPIES (ESOS STUDY) (2016) Herrick AL, Pan X, Peytrignet S, Hesselstrand R, Mouthon L, Brown E, Czirjak L, et al. Conference contribution INTER SPA: SENSITIVITY AND SPECIFITY OF AUTOANTIBODIES AGAINST CD74 IN EARLY AXIAL SPONDYLOARTHRITIS (2016) Riechers E, Baerlecken NT, Baraliakos X, Bakhsh KAM, Aries PM, Bannert B, Becker K, et al. Conference contribution Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials (2016) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution APREMILAST, AN ORAL PHOSPHODIESTERASE-4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III RANDOMIZED CONTROLLED TRIALS (2016) Gladman DD, Kavanaugh A, Adebajo AO, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials (2016) Gladman D, Kavanaugh A, Adebajo A, Gomez-Reino J, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution